Neurocrine Biosciences Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments for neurological and endocrine-related disorders. ... Neurocrine Biosciences Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments for neurological and endocrine-related disorders. The primary function of Neurocrine is to address unmet medical needs within these specialized fields through its research and development efforts. The company is well-known for its product Ingrezza, a treatment for tardive dyskinesia, a movement disorder, as well as Orilissa for endometriosis pain, developed in partnership with AbbVie. Neurocrine Biosciences significantly impacts the healthcare and pharmaceutical industries by advancing therapies for complex conditions that lack effective treatments. The company maintains a strong presence in the market through its robust pipeline of potential therapies, targeting diseases like Parkinson’s and congenital adrenal hyperplasia. Founded in 1992 and headquartered in San Diego, California, Neurocrine continues to leverage cutting-edge science to improve patient outcomes, underlining its role as a leader in the biopharmaceutical sector dedicated to neurological and endocrine health.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Greenhouse Gas (GHG) Emissions data disclosed by Neurocrine Biosciences

We reviewed Neurocrine Biosciences's website and available disclosure materials for the 2024 reporting period and did not identify any reported Greenhouse Gas (GHG) Emissions data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review Neurocrine Biosciences's data?

Create a free Tracenable account to signal interest in having our team review data for Neurocrine Biosciences.

Legal Center Contact Us